BSGM (BioSig Technologies) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is BioSig Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BioSig Technologies is: No Data: Cannot be evaluated.

Competitive Comparison of BioSig Technologies's Risk Assessment

For the Medical Devices subindustry, BioSig Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioSig Technologies's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioSig Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BioSig Technologies's Risk Assessment falls into.

BioSig Technologies (NAS:BSGM) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BioSig Technologies Risk Assessment Related Terms

Thank you for viewing the detailed overview of BioSig Technologies's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

BioSig Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioSig Technologies Inc (NAS:BSGM) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Greens Farms Road, 1st Floor, Westport, CT, USA, 06880

Website

https://www.biosig.com

BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care.

Executives

Kenneth L Londoner	director, 10 percent owner	10 RED COAT ROAD, WESTPORT CT 06880
Steven J Buhaly	officer: Chief Financial Officer	1195 NW LOMPTON DRIVE, BEAVESTON OR 97006
John Sieckhaus	officer: Chief Operating Officer	C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
Steve Chaussy	officer: Chief Financial Officer	9780 E AVE, HESPERIA CA 92345
Patrick Joseph Gallagher	director	275 PLEASANT HILL RD., FLANDERS NJ 07836
Gray Fleming	officer: Chief Commercial Officer	C/O BIOSIG TECHNOLOGIES, INC., 55 GREENS FARMS ROAD, WESTPORT CT 06880
James L Klein	director	2300NE BROOKWOOD PKWY, HILLSBORO OR 97124
Frederick Hrkac	director	C/O BIOSIG TECHNOLOGIES, 55 GREENS FARMS ROAD, WESTPORT CT 06880
James J Barry	director	C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Jeffrey F Odonnell	director	126 ROSSMORE DRIVE, MALVERN PA 19355
Anthony P. Zook	director	C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Martha Pease	director	33 SEAVIEW, MADISON CT 06443
John M Kowalski	officer: VP of Sales	54 WILTON ROAD, 2ND FLOOR, WESTPORT CT 06880
Samuel E Navarro	director	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044